Two FDA Officials Quarrel Over Safety Of Angiotensin Receptor Blockers

Two FDA officials are quarreling in public about their different views about the safety of angiotensin-receptor blockers (ARBs), according to a story by Thomas Burton in Friday’s Wall Street Journal.

One official, Thomas Marciniak, contends that ARBs may increase the risk of cancer. Marciniak has been a vocal critic of FDA’s efforts to assess drug  safety. In the past he has raised questions about other major drugs, including prasugrel, rosiglitazone, and rivaroxaban. But Marciniak’s boss, Ellis Unger, who is the acting director of the office of new drugs, told the WSJ  that Marciniak’s concerns are a “diversion.”

Click here to read the full story on Forbes.

 

English: Logo of the .

 

 

Trackbacks

  1. […] Two FDA Officials Quarrel Over Safety Of Angiotensin Receptor Blockers […]

Leave a Reply

%d bloggers like this: